Variations in time to benefit among clinical trials of cholesterol-lowering drugs

Ray, 2005, Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial, J Am Coll Cardiol, 46, 1405, 10.1016/j.jacc.2005.03.077 Sacks, 1996, The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels, N Engl J Med, 335, 1001, 10.1056/NEJM199610033351401 Rubins, 1999, Gemfibrozil for secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol, N Engl J Med, 341, 410, 10.1056/NEJM199908053410604 Yusuf, 2016, Cholesterol lowering in intermediate-risk persons without cardiovascular disease, N Engl J Med, 374, 2021, 10.1056/NEJMoa1600176 Holmes, 2013, Rationalizing prescribing for older patients with multimorbidity; considering time to benefit, Drugs Aging, 30, 655, 10.1007/s40266-013-0095-7 1994, Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S), Lancet, 344, 1383 Ridker, 2008, Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein, N Engl J Med, 359, 2195, 10.1056/NEJMoa0807646 Schwartz, 2001, Effect of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study: a randomized controlled trial, JAMA, 285, 1711, 10.1001/jama.285.13.1711 Shepherd, 1995, Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia, N Engl J Med, 333, 1711, 10.1056/NEJM199511163332001 Colhoun, 2004, Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicenter randomised placebo-controlled trial, Lancet, 364, 685, 10.1016/S0140-6736(04)16895-5 2002, MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial, Lancet, 360, 7, 10.1016/S0140-6736(02)09327-3 Downs, 1998, Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS, JAMA, 279, 1615, 10.1001/jama.279.20.1615 Sever, 2003, Lancet, 361, 1149, 10.1016/S0140-6736(03)12948-0 1998, Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels, N Engl J Med, 339, 1349, 10.1056/NEJM199811053391902 Shepherd, 2002, Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial, Lancet, 360, 1623, 10.1016/S0140-6736(02)11600-X Nakamura, 2006, Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial, Lancet, 368, 1155, 10.1016/S0140-6736(06)69472-5 Baigent, 2011, The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomized placebo-controlled trial, Lancet, 377, 2181, 10.1016/S0140-6736(11)60739-3 Cannon, 2004, Intensive versus moderate lipid lowering with statins in acute coronary syndromes, N Engl J Med, 350, 1495, 10.1056/NEJMoa040583 LaRosa, 2005, Intensive lipid lowering with atorvastatin in patients with stable coronary disease, N Engl J Med, 352, 1425, 10.1056/NEJMoa050461 Pedersen, 2005, High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction. The IDEAL study: a randomized controlled trial, JAMA, 294, 2437, 10.1001/jama.294.19.2437 1984, The Lipid Research Clinics Coronary Primary Prevention Trial results, JAMA, 251, 35 Frick, 1987, Helsinki Heart Study: Primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia, N Engl J Med, 317, 1237, 10.1056/NEJM198711123172001 Cannon, 2015, Ezetimibe added to statin therapy for acute coronary syndromes, N Engl J Med, 372, 2387, 10.1056/NEJMoa1410489 Sabatine, 2017, Evolocumab and clinical outcomes in patients with cardiovascular disease, N Engl J Med, 376, 1713, 10.1056/NEJMoa1615664 Steg 2017, Effects of anacetrapib in patients with atherosclerotic vascular disease, N Engl J Med, 377, 1217, 10.1056/NEJMoa1706444 Collins, 2016, Interpretation of the evidence for the efficacy and safety of statin therapy, Lancet, 388, 2532, 10.1016/S0140-6736(16)31357-5 Waters, 1999, Cholesterol lowering: should it continue to be the last thing we do?, Circulation, 99, 3215, 10.1161/01.CIR.99.25.3215 Mason, 2006, Active metabolite of atorvastatin inhibits membrane cholesterol domain formation by an antioxidant mechanism, J Biol Chem, 281, 9337, 10.1074/jbc.M513000200 Jacob, 2013, Atorvastatin active metabolite inhibits oxidative modification of small dense low-density lipoprotein, J Cardiovasc Pharmacol, 62, 160, 10.1097/FJC.0b013e318294998d Mason, 2016, Eicosapentaenoic acid inhibits oxidation of apoB-containing lipoprotein particles of different size in vitro when administered alone or in combination with atorvastatin active metabolite compared with other triglyceride-lowering agents, J Cardiovasc Pharmacol, 68, 33, 10.1097/FJC.0000000000000379 Ford, 2016, Long-term safety and efficacy of lowering low-density lipoprotein cholesterol with statin therapy. 20-year follow-up of West of Scotland coronary prevention study, Circulation, 133, 1073, 10.1161/CIRCULATIONAHA.115.019014 Waters, 2017, The evolution of myocardial infarction: when the truths we hold to be self-evident no longer have evidence, Can J Cardiol, 33, 1209, 10.1016/j.cjca.2017.07.001